Compare BridgeBio Pharma Inc (BBIO) vs Freeport-McMoRan Inc (FCX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Freeport-McMoRan Inc — how do they compare? BridgeBio Pharma Inc trades at $84.99 (market cap $16.39B), while Freeport-McMoRan Inc trades at $68.19 (market cap $96.91B). The key difference: Freeport-McMoRan Inc is far larger — about 5.9× BridgeBio Pharma Inc's market cap, and Freeport-McMoRan Inc pays a 0.87% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | FCX | |
|---|---|---|
Market Cap | $16.39B | $96.91B |
Sector | Health | Basic Materials |
52-Week High | $90.17 | $71.73 |
52-Week Low | $47.29 | $35.34 |
Enterprise Value | $18.16B | $103.19B |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.64, down 1.22% on the day, with a bullish technical signal from moving averages and strong analyst support. Revenue surged to $502.08M in 2025, though net losses widened to -$724.93M, reflecting high R&D spending. Recent news highlights Q2 2026 earnings misses but revenue beats, driven by Attruby sales growth and three late-stage regulatory submissions expected by mid-2027.
Outlook remains optimistic with an 88% buy rating and $104.56 price target, but risks include persistent cash burn, high debt of $1.72B, and negative equity. Key catalysts are FDA decisions in 2027, with success potentially driving significant upside, though failure could exacerbate financial strain.
FCX trades at $69.23, down 1.84% on the day, with a bullish technical signal supported by moving averages and strong support at $68. The company reported Q2 2026 EPS of $0.68, beating estimates, and maintains robust cash flow from operations of $5.61 billion in 2025. Recent news highlights growth from Grasberg ramp-up and copper market tailwinds.
Outlook is positive with a consensus price target of $73.85, reflecting 6.7% upside, driven by earnings beats and expansion projects. Risks include commodity price volatility and execution challenges at new mines. Analyst sentiment is strongly bullish with 61% buy ratings, but overbought RSI levels suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Freeport-McMoRan Inc
Freeport-McMoRan Inc is an international mining company. It operates geographically diverse assets with proven and probable mineral reserves of copper, gold and molybdenum. The company's portfolio of assets includes the Grasberg minerals district in Indonesia
Read more on FCX →
